Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.

@article{Zalcberg1998PhaseIS,
  title={Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.},
  author={John R Zalcberg and Michael Millward and James F. Bishop and Mark J. McKeage and Allan Solomon Zimet and Guy C. Toner and Michael Friedlander and C. E. Barter and Danny Rischin and Camille Loret and Roger James and N Bougan and Jocelyne B{\'e}rille},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1998},
  volume={16 5},
  pages={
          1948-53
        }
}
PURPOSE Docetaxel (Taxotere, Rhone-Poulenc Rorer, Antony, France) and cisplatin are two of the most active single agents used in the treatment of non-small-cell lung cancer (NSCLC). A recently reported phase I study of the combination of docetaxel and cisplatin recommended a dose of 75 mg/m2 of both drugs every 3 weeks for subsequent phase II study. PATIENTS AND METHODS Eligible patients were aged 18 to 75 years with a World Health Organization (WHO) performance status < or = 2 and life… CONTINUE READING
Highly Cited
This paper has 40 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations